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There has been a resurgence in clinical research of vaccine therapies,
particularly for the treatment of melanoma. The renewed interest in this
field is attributable to an increased understanding regarding the immune
response to tumors and the immunobiology of melanoma. Molecular bi-
ology techniques have enabled investigators to develop genetically engi-
neered tumor vaccines that are intended to favor the type 1 immune
response over the type 2 response. Melanoma-associated antigens have
been characterized at the molecular level and are currently being investi-
gated in clinical trials. Dendritic cell biology has also provided a potent
method to present antigens to the host for immunization. Lastly, vaccines
are being explored as a method to generate immune T-cells for adoptive
immunotherapy. These new areas of clinical investigation will be re-
viewed in the context of the historical developments that have laid the
foundations of this field.J. Surg. Oncol. 1999;70:263–274. © 1999 Wiley-Liss, Inc.
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INTRODUCTION
The concept of sensitizing the human immune system
by exposing it to foreign antigenic material, in an attempt
to protect prophylactically against a fatal infectious dis-
ease, was pioneered by Dr. Edward Jenner over 200 years
ago. His work resulted in the advent of the smallpox
vaccine and eventual eradication of this disease. Ap-
proximately 100 years later, Dr. William B. Coley (Fig.
1) extended the concept of vaccine therapy to neoplastic
diseases when he observed tumor regression in a patient
with a systemic bacterial infection. He went on to infect
deliberately cancer patients with both live and heat-killed
bacteria (Coley’s toxins) in an attempt to stimulate the
elimination of the tumor cells by the patient’s own im-
mune system. Complete tumor regression was seen in
some individuals, but overall his results were inconsis-
tent, and this approach was eventually discontinued [1,2].
Over the ensuing years, there has been increasing evi-
dence that melanoma is one of the more immunogenic
human solid tumors. It is well known by clinicians that
cutaneous melanomas can demonstrate partial regression
of the primary lesion, thus giving rise to the classic di-
agnostic features of variation in color and irregular bor-
ders. These characteristics have been attributed to a spon-
taneous host antitumor phenomenon. Laboratory investi-
gators have shown that blood from melanoma patients
contain antibodies against tumor antigens [3] and that
patients with localized melanoma or those who have un-
dergone spontaneous regression of their primary mela-
noma have a significantly higher incidence of antimela-
noma antibodies than those with advanced metastatic dis-
ease [4]. Cytotoxic T-lymphocytes that can kill tumor
cells in vitro in an immunologically specific manner have
been isolated from melanoma patients [5,6]. These tu-
mor-reactive cytotoxic T-lymphocytes can produce tu-
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mor regression after expansion in vitro and reinjection
into the same patient [7]. From other clinical studies, it is
known that 3%–15% of cutaneous melanomas are first
diagnosed as lymphatic or visceral metastases with no
physical evidence of a primary tumor. The ability to cure
a subgroup of these patients with surgical resection sug-
gests that immunological mechanisms are capable of
managing residual micrometastatic disease [8]. All these
observations lend credence to the notion that melanoma
tumors express antigens that can serve as targets for im-
munotherapy. This review article will focus on the de-
velopment of vaccines for melanoma with specific ref-
erences to basic immunological principles required for




The initial attempts at treating melanoma were with
nonspecific immunostimulants to induce host responses
against tumor without targeting specific antigens. Similar
to Coley’s early observations, Morton et al. [4] later dem-
onstrated that intralesional injection of viableBacillus
Calmette-Guerin(BCG) organisms could lead to the re-
gression of intradermal metastases of melanoma. More
interesting was the fact that nearby uninjected lesions
occasionally regressed as well. These findings provided
the rationale to investigate BCG as an immune adjuvant
after resection of melanomas in patients with a high risk
of relapse. Table I summarizes all of the prospective
randomized trials that evaluated BCG as an immune ad-
juvant [9–17]. Unfortunately, BCG did not prove to be
effective in reducing relapses after resection. Other non-
specific immunostimulants have been evaluated. Dinitro-
chlorobenzene (DNCB) is a synthetic primary allergenic
molecule that can be used to test the cellular immune
c mpetence of an individual for delayed-type hypersen-
sitivity reactions. It has also been used topically and in-
tralesionally for locoregional control of recurrent mela-
noma. Like BCG, DNCB has been associated with iso-
lated cases of tumor regression in nontreated skin or
lymph node metastasis, suggesting that a systemic im-
une reaction can be induced [18,19]. Additional non-
specific immunostimulants studied clinically includeCo-
rynebacterium parvum,levamisole, transfer factor, iso-
prinosine, and thymic factor, thymostimulin. However,
in the adjuvant setting, none of these immunostimulant
agents alone has proved to be effective in prolonging
survival in melanoma patients [20]. Currently, nonspe-
cific agents are usually administered as an adjuvant com-
bined with tumor antigens to enhance the overall immune
reactivity and augment a tumor-specific response.
Tumor Cell Vaccines
Unlike nonspecific immunostimulants, tumor-derived
vaccine reagents are designed to elicit a host immune
Fig. 1. William B. Coley, MD, was a general surgeon in New York
City during the 1890s. (Photograph courtesy of Dr. Helen Coley
Nauts.)





ECOG [9] 1979 443 II, III N.S.
UCLA [10] 1981 91 III N.S.
137 I, II N.S.
MSKCC [11] 1981 47 III N.S.
NCI [12] 1981 83 II, III N.S.
WHO [13] 1982 388 II, III N.S.
U. Alberta [14] 1984 199 II, III N.S.
RPMI [15] 1987 57 I, II, III N.S.
NCI-Canada [16] 1991 273 I, II, III N.S.
EORTC [17] 1993 327 II N.S.
aAll studies involved intradermal BCG vs. observation. ECOG4
Eastern Cooperative Oncology Group; UCLA4 University of Cali-
fornia at Los Angeles; MSKCC4 Memorial Sloan-Kettering Cancer
Center; NCI4 National Cancer Institute; WHO4 World Health
Organization; RPMI4 Roswell Park Memorial Institute; EORTC4
European Organization for the Research and Treatment of Cancer.
bTotal 4 2,045.
cN.S. 4 not significant.
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response to known or as yet uncharacterized tumor-
associated antigens. A list of tumor antigens associated
with melanoma is summarized in Table II [21–36]. In
this regard, vaccine therapy has also been termed “active
specific immunotherapy.” The immune response to ac-
tive specific immunotherapy is both humoral and cell-
mediated. Humoral immunity consists of antibody pro-
duction from mature B-lymphocytes and usually in-
volves the presence of antigen-specific helper T-cells.
Cellular immunity involves stimulation of CD4+ helper
T-cells by processed tumor antigens present on the sur-
face of a “professional” antigen-presenting cell (i.e., a
dendritic cell as opposed to a tumor cell). This interaction
is restricted to antigen-presenting cells and CD4+ T-cells
that express the same major histocompatibility (MHC)
class II molecules. Two different functional subsets of
CD4+ helper T-cells can be generated through this inter-
action and are characterized by the profiles of cytokines
that they secrete. Type 1 (Th1) cells principally secrete
interleukin-2, interferon-g, and tumor necrosis factor-a,
while type 2 (Th2) cells primarily secrete interleukin-4,
interleukin-5, interleukin-6, and interleukin-10. Th1
CD4+ helper T-cells can enhance the induction of CD8+
cellular cytotoxic T-lymphocyte response, whereas Th2
cells exert their effect on humoral immunity by inducing
B-lymphocytes to differentiate into antibody-producing
cells. Several studies suggest that type 2 responses of
T-cells can have a negative impact on, or suppress, type
1 T-cell responses [37,38]. The sensitization or induction
of CD8+T-cells to react to tumor antigen also requires the
interaction of dendritic cells that have been previously
activated by CD4+ cells [39]. Both the activation and
effector phases of these interactions are summarized in
Figure 2. An effective tumor vaccine requires activation
of both CD4+ and CD8+ cell-mediated immune re-
sponses; namely, a class II-restricted Th1 helper response
followed by class I-restricted killer cell response, respec-
tively.
Autologous Whole-Cell Vaccines
Whole tumor cells inactivated by irradiation so they
are not capable of growth can be effective vaccine agents
in syngeneic animal tumor models. Autologous tumor
cells used as vaccines have the theoretical advantage of
ensuring that all biologically relevant antigens are pre-
sented to the immune system. However, this approach is
limited to individuals with sufficient tumor available to
prepare a vaccine. Such patients typically have bulky
nodal or distant metastatic disease. Furthermore, patients
usually have significant residual tumor burdens that can
induce immunosuppressive effects, making them less
than ideal candidates for an immunotherapeutic ap-
proach. Nevertheless, vaccine approaches in this group
of patients have resulted in a subgroup of patients who
have responded to therapy.
Berd et al. [40,41] have conducted clinical studies in
patients with stage IV melanoma utilizing autologous
tumor vaccines. In their protocols, autologous whole-cell
tumor vaccine preparation involved taking freshly ex-
ised tumor, dissociating the tumor into a single cell
suspension, and then cryopreserving the cells in liquid
nitrogen. Three days prior to vaccination patients receive
intravenous cyclophosphamide as an adjuvant. Low
doses of cyclophosphamide, as used in this trial, are
thought to reduce the tumor-induced suppression ob-
served in experimental models. On the day of vaccination
the melanoma cells were thawed, irradiated, and com-
bined with BCG. The autologous vaccine was adminis-
tered by intradermal injections in the extremities, with
repetition of the cycle every 4 weeks. A nonrandomized
trial of this autologous tumor vaccine demonstrated a
12.5% response rate [41]. Antitumor responses were as-
sociated with the development of delayed-type hypersen-
sitivity to autologous melanoma cells assessed by skin
testing. This suggested that an intact host immune re-
sponse was required for vaccine-induced tumor regres-
sion.
It has been shown in a murine model that presentation
of tumor cells conjugated to a strongly immunogenic
hapten, such as trinitrophenyl, can induce the develop-
ment of systemic T-cell immunity to unmodified tumor
cells [42]. Berd et al. [40,41] have developed an autolo-
gous whole-cell melanoma vaccine approach that em-
ploys a hapten modification of the above preparation in
an effort to induce a tumor inflammatory response in
metastatic melanoma patients. Dinitrophenyl (DNP) is
utilized as the hapten and is conjugated to the autologous
melanoma cells during vaccine preparation. Patients are
sensitized to DNP by topical application of dinitrofluo-
robenzene prior to vaccine administration. This treatment
has been reported to induce inflammatory responses in
TABLE II. Defined Melanoma Antigens
Antigen
Mechanism of recognition
Cell type HLA restriction
Ganglioside carbohydrate epitopes
GM2 [21] B Not restricted
GD2 [22] B Not restricted
9-0-acetyl GD3 [23] B Not restricted
Peptide epitopes
MAGE-1 [24] T HLA-A1, -Cw*1601
MAGE-3 [25] T HLA-A3
BAGE [26] T HLA-Cw*1601
GAGE [27] T HLA-Cw6
MART-1 (Melan-A) [28] T HLA-A2
gp100 (pmel 117) [29,30] T HLA-A2
gp75 (TRP-1) [31] T HLA-A31
Tyrosinase [32–35] T HLA-A2, -A24, -B44,
-DRB1*0401
CDK4 [36] T HLA-A2
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metastases, and also significantly increases disease-free
survival and overall survival in patients with bulky re-
sectable nodal metastasis when compared to surgery
alone [43]. Interesting immunologic findings include
marked infiltration of metastases with CD8+ T-lympho-
cytes, presence of m-RNA for interferon-g, and the ap-
pearance of novel T-cell receptor Vb structures in pa-
tients with metastatic melanomas in which inflammation
was induced by the DNP-modified vaccine [43–45]. The
concept of attaching an immunogenic molecule to the
tumor cell to make it a more effective vaccine is utilized
as a rationale for investigating genetically modified tu-
mor cells as vaccines.
Allogeneic Polyvalent Vaccines
Polyvalent melanoma cell vaccine. The polyvalent
“antigen-enriched” whole-cell melanoma vaccine
(PMCV) described by Morton et al. [46] is a live-cell
preparation of three allogeneic melanoma cell lines cho-
sen for their high content of immunogenic tumor-
associated antigens and melanoma-associated antigens.
The cell lines are grown separately, harvested, combined
in equal parts, irradiated, and then cryopreserved in liq-
uid nitrogen. Patients receive biweekly intradermal in-
jections of PMCV during a 12-week induction phase.
The first two vaccinations are given with BCG. The pa-
tient then receives monthly vaccinations during the first
year followed by injections every 2–3 months thereafter.
A phase II trial of PMCV for stage IV melanoma patients
showed a higher median survival for vaccine recipients
(23.1 months) vs. historical control patients receiving
other therapies (7.5 months) [47,48]. Survival was sig-
nificantly related to the development of delayed cutane-
ous hypersensitivity to the melanoma antigens and in-
duction of antimelanoma IgM antibody titers. Another
phase II trial of PMCV for stage III melanoma revealed
a significantly higher median survival for patients receiv-
ing adjuvant therapy with PMCV following complete
resection of regional metastases compared to a historical
Fig. 2. Schematic diagram of cellular interactions involved in the activation of T-cells resulting in tumor recognition.(A) Activation phase of
both CD4+ and CD8+ T-cells require priming by antigen-presenting cells (APC). CD4+ T-cells require MHC class II restriction and costimulation
with CD28/B7 and CD40L/CD40 ligand-receptor interactions. This results in Th1 cytokine release to provide help for CD8+ T-cell activation
as well as activating APC to prime CD8+ cells to antigen. Th2 cytokines released by CD4+ cells stimulate B-cells to produce antibodies.(B) The
effector phase involves CD8+ T-cells primed to tumor antigen. Upon engagements with tumor cells presenting antigen via MHC class I
molecules, a type 1 (Tc1) or type 2 (Tc2) cytokine response occurs, which can result in tumor destruction or suppression of the immune response,
respectively. Note that not all of the costimulatory interactions between T-cells, APC, and tumor cells are depicted.
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control group that received other postoperative adjuvant
therapies (>80 vs. 24 months, respectively) [48]. A phase
III prospective randomized trial of adjuvant PMCV vs.
interferon-a for stage III melanoma patients was begun
last year at the John Wayne Cancer Institute.
This polyvalent melanoma cell vaccine induced IgM
and IgG antibodies to a 90-kDa glycoprotein melanoma-
associated antigen (TA90) [49]. In stage IV melanoma
patients postoperative TA90 immmune complex (TA90-
IC) levels prior to adjuvant therapy with PMCV corre-
lated with survival. Median and disease-free overall sur-
vival were significantly higher for patients with negative
prevaccine TA90-IC levels than for those with positive
TA90-IC levels. Thus prevaccine TA90-IC levels were
felt to be a predictor of survival in melanoma patients
receiving adjuvant immunotherapy with PMCV [50].
Viral lysates. Cell lysates of tumor cells have been
utilized as a source of tumor antigens. One method of
producing cell lysates are by infecting cells with lytic
viruses. Viral-induced oncolysis can induce long-lasting
antitumor immunity in a host by combining strong viral
antigens with weak tumor-associated antigens that result
in an enhanced immune response to the tumor antigens.
An active specific immunotherapy approach using this
methodology has been developed and evaluated by Wal-
lack et al. [51] using vaccinia virus. A vaccinia mela-
noma oncolysate (VMO) vaccine was produced by in-
fecting four established allogeneic melanoma cell lines,
Mel-2, Mel-3, Mel-4, and Mel-B, with live vaccinia vi-
rus. The cells were incubated overnight and a nucleus-
free cell lysate containing membrane fragments of virus-
lysed cells extracted by repeated sonication and centrifu-
gation. The lysates of all four cell lines were pooled in
equal concentrations to produce a tetravalent VMO vac-
cine. This polyvalent vaccine contained a variety of
melanoma-associated antigens such as nerve growth fac-
tor receptor, Ia antigen, melanoma transferrin, melanoma
antigen-1, melanoma antigen-3, MART-1, gp100, fetal-
associated antigen, urinary tumor-associated antigen,
GD3, GD2, GM2, and high-molecular-weight glycopro-
tein antigen [52].
A phase III prospective randomized trial of VMO vs.
vaccinia virus alone has been conducted in stage III
melanoma patients after surgical resection of involved
nodes [53]. In this trial, patients received a smallpox
vaccine injection 1 week before the initiation of treat-
ment. The VMO vaccine or vaccinia virus alone was
administered intradermally near the sites of nodal basins
weekly for 13 weeks and then biweekly for 1 year. Un-
fortunately, final results at a median follow-up time of
46.3 months showed no statistically significant increase
in either disease-free interval or overall survival between
the VMO vaccine group and the vaccinia virus-alone
treatment groups. A retrospective subset analysis showed
a statistically significant improvement in survival at 2-,
3-, and 5-year intervals for a subset of males between the
ages of 44 and 57 years with one to five positive nodes,
after treatment with VMO when compared to the vac-
cinia virus alone group. The cell lines used contained
most of the HLA components; however, there were no
CTL-producing peptide antigens associated with HLA-
A2 because the VMO was prepared from cell lines that
did not express HLA-A2. This has raised the concern that
the VMO treatment may not have been able to induce an
effective cytolytic T-cell immunity to HLA-A2–
restricted tumor antigens in patients being treated [27].
Approximately 50% of individuals in the North Ameri-
can population are HLA-A2–positive.
Another vaccinia melanoma cell lysate (VMCL) vac-
cine has been developed by Hersey [54]. This vaccine
utilizes only one allogeneic melanoma cell line, but is
otherwise prepared by a method similar to that used by
Wallack et al. A phase II trial of VMCL for stage III
melanoma showed improved 5-year survival for those
treated with VMCL alone (60%) vs. both a historical
(34%) and a concurrent nonrandomized (35%) control
group [55]. The addition of low-dose cyclophosphamide
to VMCL treatment did not improve survival when com-
pared to the VMCL alone treatment group. A 400-patient
prospective, randomized study of VMCL vs. no immu-
notherapy has completed enrollment and awaits final
analysis [56].
Mechanical lysates. Mechanical disruption of cell
membranes represents an alternative method to prepare
cell membrane-associated antigens. Utilizing a high-
peed tissue homogenizer and three freeze-thaw cycles, a
mixture of mechanical lysates of two melanoma cell lines
was created by Mitchell et al. [57]. This allogeneic ho-
mogenate was used in combination along with a novel
adjuvant, DETOX (a combination of detoxified bacterial
endotoxin and mycobacterial cell wall skeletons; Ribi
ImmunoChem Research, Hamilton, MT), as a vaccine
(Melacine, Ribi ImmunoChem Research) for injection
into metastatic melanoma patients. DETOX was selected
as an adjuvant because it resembled Freund’s adjuvant
and was capable of augmenting both antibody induction
and cell-mediated immunity. The Melacine vaccine was
administered subcutaneously into the upper extremity
and buttocks on days 1, 8, 15, 22, and 36 for one or two
courses and then monthly in patients with clinical re-
sponses. Vaccine administration was associated with
minimal pain and little to no systemic toxicity.
Combined results of both phase I and phase II trials in
stage III and IV melanoma patients showed an overall
response in 20 of 106 patients; 5 of 20 had complete
r sponses and 15 partial responses. The median duration
of a response was 21 months. Overall survival was not
increased, but 12 of the responding patients have lived 2
or more years with a median survival of over 36 months
[58]. The strongest correlate of clinical response was an
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increase in precursors of cytotoxic T-lymphocytes; how-
ever, only 30% of those who generated these precursors
had an objective long-term remission of more than 1-year
duration. The failure to generate cytotoxic T-lympho-
cytes was invariably associated with failure of the vac-
cine to induce tumor shrinkage and only those patients in
which a cell-mediated response was elicited were ca-
pable of rejecting their melanoma tumors [59]. Eighteen
patients who failed to respond to at least one treatment
cycle of the Melacine vaccine were then treated with
interferon-a-2b at 5–6 × 106 U/m2 three times per week
subcutaneously for at least 2 months. Eight of the 18
patients (44%) had a major objective clinical response to
the interferon-a-2b treatment [60]. A phase III trial of
Melacine with interferon-a-2b vs. interferon-a-2b alone
is underway in patients with stage IV disease [61]. In
another trial, the Southwest Oncology Group (SWOG)
has completed enrollment of 689 patients with node-
negative, intermediate-thickness melanomas (1.5–4.0
mm) into a prospective, randomized trial evaluating Mel-
acine vs. observation after resection (Dr. Vernon K.
Sondak, personal communication). This represents the
largest prospective randomized vaccine trial ever con-
ducted. The final results of this trial await maturation
with further follow-up.
Gene-Modified Tumor Cell Vaccines
The concept of genetically modifying tumor cells to be
more immunogenic by introducing genes that encode im-
munomodulatory proteins (e.g., cytokines, costimulatory
molecules, immunogenic proteins) continues to stimulate
interest in autologous tumor vaccines. Many studies have
shown that the transduction of murine melanoma tumor
cells with a variety of cytokine genes leads to the rejec-
tion of the genetically modified cells by syngeneic hosts
[62–66]. These studies indicate that cells expressing in-
terferon-g, interleukin-2, tumor necrosis factor-a, inter-
leukin-4, interleukin-6, or interleukin-7 increase sys-
temic immunity as well, because mice vaccinated with
transduced cells rejected a subsequent challenge of non-
transduced cells, and in some cases eliminated a preex-
isting tumor. GM-CSF was the most potent stimulator of
systemic antitumor immunity of over 25 different cyto-
kines and other immunomodulators tested in a murine
melanoma model [65]. Both CD4+ and CD8+ T-
lymphocytes were required for effective vaccination with
GM-CSF, since depletion of either T-cell subset before
or after vaccination abrogated the development of sys-
temic immunity. Localized expression of GM-CSF may
specifically enhance tumor antigen presentation by host
dendritic cells, thus leading to antigen-specific T-cells.
Dranoff et al. [67] have initiated a phase I trial in stage
IV melanoma patients with a vaccination of autologous,
irradiated melanoma cells engineered to secrete GM-
CSF. Preliminary results have shown the development of
potent, specific, and long-lasting systemic immunity,
with evidence of brisk T- and B-cell responses associated
with dying tumor cells at sites of preexisting masses.
Intradermal vaccine sites showed prominent dendritic
cell accrual [68]. Cytotoxic T-lymphocytes reactive with
utologous melanoma cells were detectable after vacci-
ation, both in limiting-dilution analysis and in bulk cul-
ture without added cytokines. Analysis of the cytotoxic
T-lymphocytes showed a conversion from a purely CD8+
response to a high proportion of CD4+ clones following
vaccination, suggesting that vaccination induced MHC
class I-restricted tumor-specific killing.
Two phase I clinical trials involving autologous mela-
noma tumor cells genetically modified to secrete inter-
feron-g have been reported [69,70]. Nemunaitis et al.
[69] reported no toxicity with repeated subcutaneous in-
jections every 2 weeks for a total of six injections. There
were no measurable tumor responses observed in the five
patients treated. Abdel-Wahab et al. [70] reported on 13
patients who completed vaccination and demonstrated 8
of them developing a humoral immunoglobulin IgG re-
sponse against autologous and allogeneic melanoma
cells. Two patients with significant increases in serum
IgG had tumor responses and two additional patients
with low serum IgG responses had transient shrinkage of
nodular disease during therapy.
Defined Antigen Vaccines
A number of antigens present on melanoma cells that
could potentially serve as targets for the host immune
response have been identified (Table II). Although all of
these antigens may not be present on every tumor cell, as
the number of defined antigens increases, it becomes
progressively more likely that at least one relevant anti-
genic target can be identified for every patient’s mela-
noma. Melanoma antigens can be categorized into two
broad groups: tumor-associated antigens and melanoma-
associated antigens. Tumor-associated antigens are cell
surface products in embryologic tissues, proto-oncogene
products, or antigens associated with viral transformation
common to melanoma and other tumor cells. Melanoma-
associated antigens are primarily proteins or glycopro-
t ins found predominantly in melanomas, but can also be
expressed in normal melanocytes.
An example of a family of tumor-associated antigens
that have been used for vaccine therapy of melanoma are
the gangliosides (Table II). These are carbohydrate anti-
gens expressed on several different tumors (i.e., sarco-
mas, lung cancers) and are known to be major cell sur-
face constituents of melanoma cells. The gangliosides
GM2, GD2, and 9-0-acetyl GD3 are antigens known to be
recognized by antibodies, but not by T-cells. Monoclonal
antibodies with specificity to these gangliosides can be
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found in patients with melanoma. Furthermore, mela-
noma tumor cells expressing gangliosides can be lysed
by antiganglioside antibodies. Livingston et al. [71] have
investigated the use of GM2 ganglioside admixed with
BCG as adjuvant therapy for patients with resected stage
III nodal disease. In this study, patients were randomized
to receive GM2/BCG vs. BCG alone. Among the patients
who were documented to develop IgM antibody re-
sponses to GM2, there was significantly improved dis-
ease-free and overall survival compared with patients in
the control group. This single-institution study is now
being evaluated in a multi-institutional cooperative study
in patients with resected stage III disease who are ran-
domized to receive GM2 in conjunction with keyhole
limpet hemocyanin (KLH) and QS21 vs. interferon-a-2b.
The KLH and QS21 are immune adjuvants documented
to be more effective than BCG in the induction of anti-
body responses to GM2 [71].
The ability to identify and grow T-cell clones that can
specifically recognize melanoma tumors in an MHC
class-restricted manner has allowed investigators to char-
acterize peptide antigens [72]. cDNA libraries generated
from tumor cells recognized by the T-cell clones are used
to transfect target cells bearing the appropriate MHC
class I or II restriction elements. The transfectants can
then be screened for recognition by the T-cell clones, and
the genes from those transfectants used to identify the
amino acid sequence of peptide antigens. These peptide
antigens generally represent fragments of protein consist-
ing of eight or nine amino acids called “epitopes” and can
be part of a larger protein antigen structure (i.e., tyrosi-
nase). A summary of known melanoma-associated pep-
tide antigens and their MHC restriction elements are
listed in Table II. Rosenberg et al. [73] have utilized
melanoma-associated peptides for vaccine therapy in pa-
tients with stage IV disease. A gp100 epitope, g209–217,
was modified (g209-2M) and bound to the HLA-A2 mol-
ecule with greater affinity than the unmodified peptide.
This peptide was shown to have an increased ability to
generate melanoma-reactive cytotoxic T-lymphocytes in
vitro. A clinical trial was conducted in HLA-A2+ patients
with metastatic melanoma using an emulsification of the
g209-2M peptide in incomplete Freund’s adjuvant in-
jected every 3 weeks. Immunologic assay of peripheral
blood mononuclear cells from patients after treatment
showed that 91% of the patients were successfully im-
munized with this synthetic peptide. In another cohort of
patients who received the peptide vaccine plus adjuvant
interleukin-2, 13 of 31 patients (42%) had objective clini-
cal responses. It was interesting to note that only a mi-
nority of these latter patients demonstrated immunologic
reactivity of their peripheral blood lymphocytes to the
peptide despite manifesting tumor regression. A prospec-
tive, randomized trial to evaluate the efficacy of this
peptide vaccine plus IL-2 vs. IL-2 alone is being con-
ducted by the Surgery Branch, NCI (Dr. Douglas
Schwartzentruber, personal communication).
Dendritic Cell-Based Vaccines
CD8+ cytotoxic T-lymphocytes appear to be a critical
component of the immune response to tumors [74].
These cytotoxic T-lymphocytes recognize peptide epi-
topes presented by class I major histocompatibility com-
plex molecules that are expressed on the tumor cell sur-
face [75]. Although the recognition of peptide class I
complexes is sufficient to trigger target cell lysis, prim-
ing of cytotoxic T-lymphocyte responses requires the
presentation of the relevant antigen by professional an-
tigen-presenting cells capable of expressing costimula-
tory molecules [76]. The presentation of tumor antigen
by antigen-presenting cells in concert with help provided
by CD4+ cells to prime these antigen-presenting cells is
crucial for the induction of a cytotoxic T-lymphocyte
response (Fig. 2) [39].
Dendritic cells are rare leukocytes named for their stel-
late morphology and are considered to be the most potent
of all antigen-presenting cells [77]. Dendritic cells are
generated in the bone marrow, course through the blood
stream, migrate into the tissues, and become strategically
located at sites of potential antigen exposure. These cells
are capable of responding to cytokines at a locus of in-
flammation, acquiring antigen, carrying it to the adjacent
lymph nodes, sensitizing naive T-cells to defined anti-
gen, and eliciting a primary T-lymphocyte response [78].
Dendritic cells are the only natural antigen-presenting
cells that have been shown to prime naive T-lymphocytes
both in vitro and in vivo, and they express high levels of
costimulatory molecules (B7.1, B7.2, and CD40). Given
these properties, dendritic cells have been proposed as
the ideal candidates for the induction of antitumor im-
munity in a vaccine setting.
Autologous dendritic cells can be obtained in large
numbers by differentiation of peripheral blood mono-
cytes in the presence of GM-CSF and interleukin-4 [79].
These cultured dendritic cells maintain the antigen cap-
turing and processing capacity characteristic of immature
dendritic cells in vivo. An alternative approach involves
the induced differentiation of bone marrow CD34+ pro-
genitors to dendritic cells by G-CSF stimulated mobili-
zation and subsequent culture with GM-CSF, TNF-a,
stem cell factor, and FLT3 ligand [80,81]. CD34+-
derived dendritic cells have been shown to be more ef-
f cient in the activation of Mart-1–specific CTLs from
low-frequency precursors than dendritic cells derived
from monocytes [81].
Bone marrow-derived dendritic cells generated by cul-
ture with GM-CSF and interleukin-4, then pulsed with
major histocompatibility class I peptide antigen, are ca-
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pable of completely immunizing naive mice against a
subsequent lethal tumor challenge by tumor transfected
with the antigen gene in a murine M05 melanoma model
[76]. In addition, these peptide-pulsed dendritic cells ex-
hibit a strong peptide-specific cytotoxic T-lymphocyte
response in vitro [82]. The immunity is antigen-specific,
requiring expression of the antigen gene by the tumor
target, and is eliminated by in vivo depletion of CD8+
T-cells.
In a recent phase I study reported by Nestle et al. [83],
dendritic cells were generated from peripheral blood us-
ing GM-CSF and interleukin-4. These dendritic cells
were pulsed with either melanoma tumor lysate or a
cocktail of melanoma peptides known to be recognized
by cytotoxic T-lymphocytes, depending on the patient’s
HLA haplotype. KLH was added as a helper antigen and
immunological tracer molecule. Sixteen patients with
stage IV disease were treated on an outpatient basis. Den-
dritic cell preparations were injected into an uninvolved
inguinal lymph node at weekly and monthly intervals for
up to 10 vaccinations, depending on clinical response.
Vaccination was well tolerated in all patients. Objective
responses were observed in 5 of 16 treated patients (two
complete, three partial responses) with regression of me-
tastasis in various organs (skin, soft tissue, lung, and
pancreas). Besides pulsing dendritic cells with tumor ly-
sates or known peptide antigens, investigators have re-
ported that it is possible to introduce genes encoding
tumor antigens into these cells, which result in their abil-
ity to prime T-cells [84,85]. These various approaches of
pulsing dendritic cells are being evaluated in clinical tri-
als at various institutions (Fig. 3).
Future Approaches to Tumor Vaccines
The combination of vaccination therapy in conjunction
with exogenously administered cytokines will be evalu-
ated more extensively in clinical trials in the near future.
As noted above, peptide vaccines administered in con-
junction with IL-2 was associated with measurable tumor
responses in patients with stage IV disease compared to
peptide vaccine alone [73]. The immunopotentiating ef-
fect of certain cytokines appear to augment the antitumor
response induced by vaccine therapies. This has been
well-documented in preclinical animal models. Both IL-2
and IL-12 systemic administration have been shown to
potentiate the effects of active specific immunotherapy in
animal studies [86,87]. IL-2 is a growth factor for acti-
vated T-cells while IL-12 facilitates the induction of Th1
cells.
A novel molecular-based approach to autologous tu-
mor cell vaccines is the in situ genetic modification of
tumors with immunostimulatory genes. Using a plasmid
encoding an allogeneic MHC class I gene that was com-
plexed to liposomes, Plautz et al. [88] reported that the
direct intratumor inoculation of this nonviral vector re-
sulted in regression of established subcutaneous tumors.
Analysis of this phenomenon revealed that the in vivo
lipofection of the tumor with an allogeneic class I gene
resulted in T-cell immunity to the allogeneic class I an-
tigen as well as native tumor antigens. Presumably, the
expression of foreign MHC class I molecules within the
tumor resulted in a brisk inflammatory response that en-
hanced the induction of immunity to tumor antigen. Ad-
vantages of this technique to modify molecularly tumors
in situ is the avoidance of viral vectors and bypassing the
need to culture tumor cells ex vivo for gene transfer,
which is labor-intensive and time-consuming. Gene ex-
pression was required in >10% of the tumor cells to
achieve an immunologic response. Clinical studies inves-
tigating this approach have been carried out at the Uni-
versity of Michigan. These studies involved the treatment
of stage IV melanoma patients who were administered a
plasmid encoding for the HLA-B7 class I molecule in-
oculated intratumorally three times over the course of 1
month [89,90]. Patients were required to be HLA-B7–
negative to be eligible for the study. Successful gene
expression was documented in the majority of patients,
and in isolated cases tumor regression of the injected
lesions were observed. Of interest with these studies was
the assessment of the immune reactivity of T-cells de-
rived from tumor after gene injections compared to pre-
treatment tumor-associated T-cells. These tumor-infil-
trating lymphocytes (TIL) were cultured and assayed for
reactivity to autologous tumor by measuring cytokines
released by the TIL in in vitro assays where irradiated
autologous or allogeneic tumor cells were added as
stimulator cells (Fig. 4). TIL were found to be more
reactive to autologous tumor cells after HLA-B7 therapy
compared to pretreatment; this response was immuno-
logically specific. A clinical trial to treat patients with
TIL derived from tumors inoculated with this gene
is currently underway at the University of Michigan
(Fig. 5).
Fig. 3. Schematic diagram of dendritic cell protocols being evaluated
in clinical trials.
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The technology of delivering genes in situ has major
implications to vaccine therapies. Besides lipofection
techniques as described above, another nonviral gene
transfer method that has higher efficiency rates is the use
of the gene gun. The gene gun involves shooting gold
particles complexed with gene onto target tissues such as
tumor or skin. The gold particles are projected into the
tissue by compressed gases, i.e., helium. The particles
enter the cells and the gene of interest is transcribed in an
episomal fashion. An illustration of how the apparatus
appears and is utilized in an animal model is depicted in
Figure 6. Genes encoding tumor antigens, immunostim-
ulatory molecules (e.g., MHC antigens, costimulatory
molecules, superantigens, heat shock proteins, etc.), or
cytokines can be delivered using this methodology [91].
It has the advantages of employing nonviral vectors and,
because of its localized delivery, may be useful intraop-
eratively after exposure of a tumor.
As described above, direct gene transfer into a pro-
gressively growing tumor is one method to derive en-
hanced tumor-reactive T-cells (i.e., TIL) for use in adop-
tive immunotherapy. Our laboratory has used vaccines to
induce tumor-reactive T-cells in draining lymph nodes
which we have documented can be expanded ex vivo and
used in adoptive immunotherapy to mediate tumor re-
gression [92–94]. Based on extensive preclinical studies,
we have conducted clinical trials involving vaccines
comprised of autologous tumor cells admixed with BCG
to prime draining lymph nodes that can be harvested, ex
vivo expanded, and used for adoptive immunotherapy
[95]. More recently, we have examined the use of gene-
modified tumor cells as a method to prime draining
lymph nodes for adoptive immunotherapy. In a murine
melanoma model, we have found that tumor cells modi-
fied to secrete GM-CSF are more potent than tumor cells
engineered to secrete IL-2, interferon-g, or IL-4 to prime
draining lymph node cells [96,97]. Moreover, GM-CSF
secretion was more effective than admixing a bacterial
adjuvant in generating “vaccine-primed” lymph nodes
cells used in adoptive immunotherapy. We are currently
conducting a clinical trial in melanoma patients to evalu-
ate the utility of genetically engineered autologous tumor
cells to prime draining lymph nodes for adoptive immu-
notherapy [98].
Fig. 5. Schematic diagram of a TIL trial being performed at the
University of Michigan. TIL are primed in vivo by the intratumoral
inoculation of HLA-B7 plasmid complexed with liposomes.
Fig. 4. Cytokine release profile of TIL cells derived from a melanoma patient before and after in situ HLA-B7 transfection. Enhanced
interferon-g, GM-CSF, and TNFa was released by the TIL after gene transfer compared to before treatment. This response was immunologically
specific since cytokine release was stimulated by autologous tumor cells, and not allogeneic tumor cells.
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CONCLUSION
Melanoma represents one of the few solid malignan-
cies where immunotherapy has become a standard mode
of therapy. For resected stage III disease, interferon-a-2b
has been identified to have a significant effect on pro-
longing both disease-free and overall survival [62]. Un-
fortunately, this therapy is associated with significant
side effects, and it is hoped that vaccines may eventually
replace interferon-a-2b as an adjuvant therapy. It is pre-
dicted that the process of vaccination with tumor anti-
gens, namely active specific immunotherapy, will have
its greatest efficacy in the setting of residual micrometa-
static disease. There are several clinical trials currently
underway to test these hypotheses. Other advances in
vaccine development involve molecular engineering of
tumor cells, the characterization of melanoma-associated
peptide antigens, and the development of cellular re-
agents for use in immunotherapy (i.e., dendritic cells and
primed T-cells). These investigations have led to encour-
aging clinical trials in melanoma patients with stage IV
disease. As we continue to increase our knowledge re-
garding the interaction of the host immune response to
vaccines and the effector mechanisms required to eradi-
cate established tumor, active specific immunotherapy
will eventually become a standard approach to treatment
of melanoma as well as other malignancies.
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